AMICUS THERAPEUTICS,INC. (NASDAQ:FOLD) Files An 8-K Results of Operations and Financial Condition

ME Staff 8-k
-
0

AMICUS THERAPEUTICS,INC. (NASDAQ:FOLD) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.

On November8, 2017, Amicus Therapeutics,Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September30, 2017. A copy of this press release is attached hereto as Exhibit99.1. The Company will also host a conference call and webcast on November8, 2017 to discuss its third quarter results of operations. A copy of the conference call presentation materials is also attached hereto as Exhibit99.2.

In accordance with General Instruction B.2. of Form8-K, the information in this Current Report on Form8-K and the Exhibitshall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits: The ExhibitIndex annexed hereto is incorporated herein by reference.


AMICUS THERAPEUTICS INC Exhibit
EX-99.1 2 a17-26227_1ex99d1.htm EX-99.1 Exhibit 99.1     Amicus Therapeutics Announces Third Quarter 2017 Financial Results and Corporate Updates   260+ Fabry Patients on Reimbursed Galafold™ (Migalastat) and On Target to Reach 300 Patients by Year-End 2017   U.S. NDA Submission for Migalastat Planned in 4Q17   Pompe Retrospective and Prospective Data Collection Studies Initiated   Additional Pompe Clinical Data to be Presented at WORLDSymposium™ in February 2018   CRANBURY,…
To view the full exhibit click here

About AMICUS THERAPEUTICS,INC. (NASDAQ:FOLD)

Amicus Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD). It has completed two Phase III global registration studies (Study 011 and Study 012) of migalastat monotherapy. It is also engaged in Phase III clinical development of a topical cream, SD-101, for the treatment of the genetic connective tissue disorder Epidermolysis Bullosa. It has also initiated a clinical study in patients with Pompe disease, a LSD to investigate its treatment paradigm that consists of ATB200, which is an engineered recombinant human acid alpha-glucosidase enzyme with an optimized carbohydrate structure to enhance uptake, co-administered with AT2221, to improve activity and stability.